Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Gemcitabine

Review the clinical trials studying gemcitabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 128

Comparing Impact of Treatment Before or After Surgery in Patients with Stage II-IIIB Resectable Non-small Cell Lung Cancer
Status: Active
Location: 329 locations
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Status: Active
Location: 297 locations
Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Invasive Bladder Urothelial Cancer
Status: Active
Location: 369 locations
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Status: Active
Location: 156 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Status: Active
Location: 126 locations
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Status: Active
Location: 79 locations
A Study Using Nivolumab, in Combination with Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Status: Active
Location: 65 locations
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy after Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active
Location: 71 locations
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Status: Active
Location: 42 locations
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Status: Active
Location: 28 locations
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Status: Active
Location: 29 locations
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Status: Active
Location: 25 locations
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Status: Active
Location: 23 locations
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Status: Active
Location: 24 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Status: Active
Location: 22 locations
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Status: Active
Location: 22 locations
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Status: Active
Location: 18 locations
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Status: Active
Location: 21 locations
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Status: Active
Location: 17 locations
A Study of ASP3082 in Adults With Advanced Solid Tumors
Status: Active
Location: 17 locations
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Status: Active
Location: 14 locations
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Status: Active
Location: 14 locations
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: 14 locations
Gemcitabine and Oxaliplatin Chemotherapy with or without a Floxuridine and Dexamethasone Pump in Patients with Cholangiocarcinoma that Cannot Be Removed with Surgery
Status: Active
Location: 10 locations
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Status: Active
Location: 12 locations